Wuhan Hiteck Biological Pharma Co.,Ltd.’s Net Profit Rose 29.6% in First Three Quarters of 2022

Wuhan Hiteck Biological Pharma Co.,Ltd. (武汉海特生物制药股份有限公司) (300683.SZ) reported a net profit of 24.7 million yuan in the first three quarters of 2022, up 29.6% year-on-year.

Meanwhile, the company posted 546.6 million yuan in revenue, up 39.3% year-on-year.

At the end of the reporting period, it had 2.7 billion yuan in total assets and 307.7 million yuan in total liabilities, with a liability-to-asset ratio of 11.5%.